Navigation Links
Gene Abnormality Found to Predict Childhood Leukemia Relapse
Date:1/7/2009

n plays an essential role in the development of lymphocytes, the white blood cells that, when changed, give rise to pediatric ALL. The way in which IKAROS abnormalities contribute to the development of relapse remains to be determined.

The study also examined gene expression in the leukemia cells using microarray chips, and found that leukemia cells from patients with IKAROS alterations expressed primitive, stem cell-like genes, suggesting that the cells are less mature and possibly more resistant to the effects of drugs used to treat ALL. "These findings show how detailed analysis of leukemic cells using complementary techniques can enhance our understanding of the genetic basis of leukemia," said co-author Cheryl Willman, M.D., director and CEO, University of New Mexico Cancer Research & Treatment Center.

The researchers also tested whether the presence of IKAROS alterations was associated with levels of minimal residual disease, another measure of treatment response in ALL.

"Measurement of levels of minimal residual disease is widely used to monitor treatment responsiveness and also to alter patients' therapy if they have a very poor response to treatment," said James Downing, M.D., St. Jude scientific director and the paper's senior author. "An important analysis we conducted was to see whether identifying the association of IKAROS alterations with poor outcome added anything to just measuring levels of minimal residual disease. And, indeed, it did."

The researchers' analysis indicated that identifying IKAROS alterations may be clinically useful and will complement existing diagnostic tests and measurement of minimal residual disease levels.

While a clinical test for alterations of IKAROS could prove valuable for predicting poor outcomes in children with ALL, complexities remain. There are different types of deletions in t
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
2. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
3. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
6. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
7. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
8. The Oral Cancer Foundation Urges HPV Vaccination for Males
9. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
10. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
11. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... PRINCETON, N.J., July 29, 2014  Covance Inc. (NYSE: ... second quarter ended June 30, 2014.  Net revenue was ... of 2013.  On a GAAP basis, the company reported ... quarter.  The company reported pro forma earnings per diluted ... of 2013. Pro forma results exclude asset impairment charges ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... 11, 2012  Star Scientific, Inc. (NASDAQ: CIGX ) ... the Journal of Neurology suggests that nicotine patches ... a professor of psychiatry at Vanderbilt University Medical Center, led ... treatment among patients who had mild cognitive impairment – often ...
... ANGELES, Jan. 11, 2012 Decision Diagnostics Corp., ... developer of revolutionary  Smart phone centric e-health care ... provider of home medical supplies and point of ... leading fulfillment provider of direct to patient diabetes ...
Cached Medicine Technology:Potential Role of Natural Alkaloids in Combatting Memory Loss 2Potential Role of Natural Alkaloids in Combatting Memory Loss 3Potential Role of Natural Alkaloids in Combatting Memory Loss 4Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology 2
(Date:7/29/2014)... 29, 2014 (HealthDay News) --,The time at which heart ... chances for survival, new research suggests. Showing up ... during holidays is associated with a 13 percent higher ... researchers report. Every year, more than 250,000 people ... type of heart attack, which is caused by a ...
(Date:7/29/2014)... Although the bite of a brown recluse spider is ... an expert notes. It,s still important to recognize ... brown recluse spider bite, warned Dr. Donna Seger, medical ... potentially dangerous bites are on the rise. "As ... The [bite] has classic characteristics, but if physicians are ...
(Date:7/29/2014)... County, NJ (PRWEB) July 29, 2014 ... two leading pediatricians have joined our network, CarePoint ... Politis and Dr. Sushma Kaki. Hundreds of highly ... Group, a comprehensive network of top doctors and ... of specialties. This latest acquisition represents CarePoint Health’s ...
(Date:7/29/2014)... Alan Mozes HealthDay ... Treating certain adult autism patients with just a single dose ... facial expressions and emotions, Japanese researchers report. Known as ... role in emotional bonding between lovers, and between mothers and ... activity in a key area of the brain that has ...
(Date:7/29/2014)... 2014 Summer is here, and that means it’s ... hike, swimming in a pool or laying out on the beach. ... ticks. The Puppy Store is here to help pet owners protect ... It’s almost impossible to completely keep fleas and ticks at bay, ... chances of their pets coming into contact with fleas and ticks. ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2
... April 27 BioTrends is pleased to announce the ... SIMPONI (R) . Cenotcor ... for SIMPONI (R) (generic name: golimumab) ... anti-TNF-alpha therapy, SIMPONI is approved for the treatment of ...
... WASHINGTON, April 27 Speaker Nancy ... virus: "This afternoon, Majority Leader Hoyer and I were ... Obama Administration,s preparations to deal with the public health ... briefed us on the efforts that are being made ...
... 27 Speaker Nancy Pelosi released the following statement ... serve as Ambassador at Large and Global AIDS Coordinator:"President ... Ambassador at Large and Global AIDS Coordinator signals the ... Dr. Goosby is an excellent choice and is uniquely ...
... April 27 Young Innovations, Inc. (Nasdaq: YDNT ... 2009. Sales for the first quarter of 2009 were ... the $24.4 million reported in the first quarter of 2008. ... first quarter of 2009 from $4.6 million in the first ...
... BAX ), will host its annual shareholders meeting ... (10:30 a.m. Central Time)This call is being webcast by Thomson/CCBN ... http://www.baxter.com/ . The conference call ... It cannot be recorded or rebroadcast without Baxter,s permission.The webcast ...
... HSKA ) announces the following Webcast: (Logo: ... to Its Annual Meeting of Stockholders on the WebWhen: ... www.heska.com (click on the Annual Meeting of ... Live over the Internet -- Simply log on ...
Cached Medicine News:Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: